Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas

Christian S. Betz; Winrich Rauschning; Evgueni P. Stranadko; Mikhail V. Riabov; Volker Albrecht; Nikolay E. Nifantiev; Colin Hopper

doi:10.1117/12.822063

13 July 2009 Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas

Christian S. Betz, Winrich Rauschning, Evgueni P. Stranadko, Mikhail V. Riabov, Volker Albrecht, Nikolay E. Nifantiev, Colin Hopper

Author Affiliations +

Proceedings Volume 7380, Photodynamic Therapy: Back to the Future; 73800P (2009) https://doi.org/10.1117/12.822063
Event: 12th World Congress of the International Photodynamic Association, 2009, Seattle, Washington, United States

Abstract

Objectives: Basal cell carcinomas (BCCs) are the most common skin cancers, and incidence rates are still rising. Photodynamic Therapy (PDT) with mTHPC (Foscan®) has shown to be a promising alternative to other treatments with good cosmetic results. This study was performed to determine optimal treatment parameters for this indication. Methods: 117 patients with a total of 460 BCCs received mTHPC-PDT. The treatment parameters were varied as follows: Foscan® dose 0.03 - 0.15 mg/kg, drug-light interval (DLI) 1 - 96 hours, total energy density 20 - 120 J/cm2. The clinical outcomes were assessed 8 weeks after PDT following WHO guidelines. Results: The rate of complete remissions (CR) was 96.7% and the general cosmetic outcome rated very good. In the largest subgroup (n=80) with low-dose mTHPC (0.05 mg/kg mTHPC; 48 hours DLI; 50 J/cm2 total energy density), a CR rate of 100% was accomplished. Minor changes of the parameters (0.04 mg/kg mTHPC or 24 hours DLI) yielded similar results. Side effects were encountered in 52 out of 133 PDT sessions. They were more common in patients who had received high drug doses (0.06 - 0.15 mg/kg) and comprised pain and phototoxic reactions. 3 patients developed severe sunburns with subsequent scarring at the injection site following sunlight exposure 2-3 weeks after mTHPC administration. Conclusions: The data suggests that low-dose mTHPC-PDT is an effective treatment option for BCCs. If sensibly applied, it is well tolerated and provides mostly excellent cosmetic results. The evaluation of long term results is still to be undertaken.

Citation Download Citation

Christian S. Betz, Winrich Rauschning, Evgueni P. Stranadko, Mikhail V. Riabov, Volker Albrecht, Nikolay E. Nifantiev, and Colin Hopper "Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas", Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73800P (13 July 2009); https://doi.org/10.1117/12.822063

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available